$BBIO
BridgeBio Pharma, Inc. Common Stock
XNAS•Health Care•Pharmaceutical Preparations
Why is BBIO up today? It is at $76.20 (+0.00%), and our scanner flagged it 60 times on unusual volume this month. See the catalyst behind the move, real-time alerts the moment BBIO spikes, and full due diligence on BBIO — key stats, earnings, dilution and insider activity. Free.
Get free $BBIO alerts the moment volume spikes
Our scanner flagged $BBIO 60 times in the last 30 days. Create a free account to track $BBIO, build a watchlist, and get instant unusual-volume alerts, with a full day of premium now and 5 more when you verify your email, no card needed.
No card · 5 premium days · join 800+ traders
Key Stats
- Price
- $76.20
- Change today
- +0.00%
- Previous close
- $76.57
- 52-week range
- $48.78 – $93.42
- Market cap
- $14.97B
- Institutional own.
- 99.9%
- Total held
- 100.0%
- Short interest
- 23.3M ▼ -0% vs prior · as of 2026-08-14
- Days to cover
- 10.8d
- Avg daily volume
- 2.7M
- Sector
- Health Care
- Industry
- Pharmaceutical Preparations
- Exchange
- XNAS
- 5mthin
- 714x
- 15mthin
- 714x
- 1hthin
- 714x
- 1D
- --
Get free BBIO + market alerts in your inbox
The top plays and unusual-volume catches our scanner flags, emailed to you. No account needed.
No spam. Unsubscribe anytime. Not investment advice.
Why is $BBIO moving today?
Here is the latest on BBIO from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for BBIO today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
Likely catalystBridgeBio Announces Agreement with U.S. Government to Improve Affordability and Access to Critical Medicines for AmericansReported - The agreement has no impact on ForgingBridges®, a copay assistance program that helps reduce out-of-pocket costs to as little as $0 per month forReported financial assistance to qualifying patients, potentially minimizing out-of-pocket costs to as little as $0 per month.Reported Diarrhea (11.6% vs 7.6%) and upper abdominal pain (5.5% vs 1.4%) were reported inpatients treated with Attruby versus placebo, respectively. The majority of these adverse reactions were mild and resolved without drug discontinuation., from the latest SEC filing. Read it →Analyst data via Nasdaq. Not investment advice.
Insiders
12 buys, 16 sells last 3 months (14/70 over 12 months)Show 12 recent transactionsMinimize 12 recent transactions
| Insider | Action | Shares | % of position | Owns after | Value | Date |
|---|---|---|---|---|---|---|
Kumar Neil Officer | Sold (automatic/other) | -10K | sold 0.2% | 4.82M | $839K at $83.86 | Aug 19, 26 |
Kumar Neil Officer | Sold (automatic/other) | -35K 0.02% of company | sold 13% | 243K | $2.8M at $81.15 | Aug 18, 26 |
Apuli Maricel Officer | Sold (automatic/other) | -5K | sold 3.7% | 123K | $376K at $79.86 | Aug 16, 26 |
Kumar Neil Officer | Sold (automatic/other) | -36K 0.02% of company | sold 12% | 278K | $2.9M at $79.86 | Aug 16, 26 |
Kumar Neil Officer | Other | 71K 0.04% of company | added 29% | 315K | n/a | Aug 16, 26 |
Trimarchi Thomas Officer | Sold (automatic/other) | -23K 0.01% of company | sold 6.3% | 337K | $1.8M at $79.86 | Aug 16, 26 |
Apuli Maricel Officer | Sold (automatic/other) | -2K | sold 1.5% | 127K | $160K at $80.06 | Jul 30, 26 |
Cook Jennifer E. Director | Sold (automatic/other) | -149K 0.08% of company | sold 95% | 8K | $12.5M at $84.00 | Jul 9, 26 |
Cook Jennifer E. Director | Other | 149K 0.08% of company | added 100% | 157K | $1.3M at $8.45 | Jul 9, 26 |
Ellis Andrea Director | Sold (automatic/other) | -17K | sold 43% | 23K | $1.4M at $84.00 | Jul 9, 26 |
Ellis Andrea Director | Other | 17K | added 76% | 40K | $288K at $16.75 | Jul 9, 26 |
Cook Jennifer E. Director | Sold (automatic/other) | -37K 0.02% of company | sold 82% | 8K | $2.6M at $70.00 | Jun 24, 26 |
Recent Form-4 filings via Nasdaq. Open-market buys are the signal worth watching. Grants and automatic (10b5-1) sells are routine. “% of position” is the share of that insider’s own holding the trade moved. Not investment advice.
Dilution watch
Recent offeringRecent priced share offering — a one-time sale that has already completed (not ongoing). If $BBIO runs, these filings show who may be positioned to sell new or newly-registered shares into the move.
Sourced from SEC EDGAR filings (last 9 months); terms read straight from the filing text where available. Ongoing = an at-the-market (ATM) program still selling over time or a live shelf, so it can keep diluting; Completed = a one-time priced sale that already finished. A shelf (S-3) stays effective ~3 years. Form type signals dilution capacity, not an exact share count, and we can't confirm how much of a shelf or ATM remains unused. Not investment advice.
$BBIO Sentiment
BullishBlend of news sentiment, today’s move, and community votes. Not investment advice.
$BBIO Activity
News, unusual-volume alerts, AI-trader trades and community chatter - the whole story, newest first.
Stocks similar to BBIO
Comparable names in pharmaceutical preparations, closest in size first.
BBIO stock FAQ
Why is $BBIO moving today?
Here is the latest on BBIO from our scanner (live price and day move above). We have not detected an unusual-volume catalyst for BBIO today, so it is trading in line with its recent range. The moment our scanner flags unusual activity, the reason will appear here.
What is the BBIO stock price today?
BBIO last traded at $76.20, up 0.00% on the day. The price and chart above update live during market hours (4 AM to 8 PM ET).
Where can I see live BBIO alerts?
The BBIO Live Alerts panel on this page streams real-time unusual volume (RVOL), momentum, halt and 200-EMA alerts from our scanner the moment they fire. Our scanner has flagged BBIO 60 times in the last 30 days.
What exchange is BBIO on?
BBIO (BridgeBio Pharma, Inc. Common Stock) trades on XNAS, with a market cap of about $14.97B in the PHARMACEUTICAL PREPARATIONS sector.
Is BBIO good for day trading?
That depends on your strategy and risk. Day traders look for volume, volatility and a clear trend. Use the live chart, RVOL alerts and 200-EMA context on this page to judge BBIO for yourself. This is not investment advice.
Live data from TheDesperateTrader scanner. Not investment advice.